Structure of Daridorexant, an oral dual-orexin receptor antagonist (DORA)

dual orexin receptor GPCR antagonist

Ph. III efficacy for insomnia, oral 25-50 mg

from optimization of prior clinical candidate

ChemMedChem., Oct. 28, 2020

Idorsia Pharmaceuticals, Allschwil, CH

Idorsia clinical dual orexin receptor GPCR antagonist


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.